Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing in vitro, molecular, and animal model research.
PubMed 18612139 · doi:10.1210/er.2007-0027
What was done
This narrative review summarizes the molecular mechanisms, in vitro findings, and in vivo animal model evidence regarding the anti-inflammatory and tissue-protective properties of alpha-melanocyte-stimulating hormone (alpha-MSH) and related tripeptides, specifically KPV and KdPT.
What was found
The abstract reports no numerical data. It describes that alpha-MSH acts via central and peripheral melanocortin receptors to modulate nuclear factor-kappaB, adhesion molecules, chemokine receptors, proinflammatory cytokines, IL-10, T cell proliferation, inflammatory cell migration, antioxidant enzymes, and apoptosis. Efficacy was documented in animal models of fever, contact dermatitis, vasculitis, fibrosis, arthritis, organ injury, and ocular, gastrointestinal, brain, and allergic airway inflammation. The C-terminal tripeptide KPV and its derivative KdPT retained anti-inflammatory activity in preclinical models without inducing pigmentation.
Why it matters
Identifying non-pigmenting tripeptide derivatives like KPV and KdPT circumvents the primary clinical barrier of full-length alpha-MSH, offering prospective candidates for treating immune-mediated inflammatory diseases.
Limits
The review relies on in vitro experiments and animal disease models with no human clinical trial data presented in the abstract. Quantitative summary statistics, effect sizes, and search methodology details are not reported.
Cited by
- contradicts The peptide KPV is used as part of the Ritchie Shoemaker protocol to increase alpha-melanocyte-stimulating hormone (alpha-MSH) in cases of mold exposure and Chronic Inflammatory Response Syndrome (CIRS).